Welcome to our dedicated page for iRhythm Holdings news (Ticker: IRTC), a resource for investors and traders seeking the latest updates and insights on iRhythm Holdings stock.
iRhythm Technologies, Inc. (NASDAQ: IRTC) generates frequent news as a digital health care company focused on long-term ambulatory cardiac monitoring and data-driven arrhythmia detection. News coverage commonly highlights clinical study results, financial performance, product-related updates for the Zio long-term continuous monitoring (LTCM) service, and the company’s participation in major medical and investor conferences.
Many announcements center on real-world evidence and clinical research. iRhythm regularly reports data from large-scale analyses and trials such as CAMELOT, AVALON, AMALFI, and studies presented at the American Heart Association Scientific Sessions, the Asia Pacific Heart Rhythm Society meetings, and other scientific forums. These updates often explore topics like diagnostic yield compared with other monitoring modalities, performance in diverse patient populations, home-based self-application of Zio devices, and earlier arrhythmia detection in at-risk groups, including those with cardio-kidney-metabolic or chronic kidney disease profiles.
Investors and clinicians following IRTC news will also find quarterly earnings releases, guidance updates, and commentary on operational trends in the company’s core Zio LTCM business, mobile cardiac telemetry initiatives, and international expansion. Additional items include information on investor presentations at healthcare conferences and updates on corporate policies or governance disclosed through press releases linked to SEC filings.
This news page aggregates these developments in one place, allowing readers to review iRhythm’s latest clinical evidence, business updates, and strategic commentary over time. For those tracking digital health, ambulatory ECG monitoring, and AI-enabled cardiac diagnostics, the IRTC news feed provides ongoing insight into how the company presents its technology, research findings, and market priorities.
iRhythm Technologies, Inc. (NASDAQ: IRTC) will announce its third quarter 2022 financial results on November 1, 2022, after market close. A conference call is scheduled for 1:30 p.m. PT (4:30 p.m. ET) to discuss the results. iRhythm specializes in digital healthcare solutions that utilize wearable biosensors and cloud-based analytics to provide actionable insights from heart data. This approach aims to improve patient care by delivering better data and health outcomes.
iRhythm Technologies (NASDAQ: IRTC) announced its strategies for long-term growth during the 2022 Analyst & Investor Day in New York City. CEO Quentin Blackford highlighted a vision for $1 billion in revenue by 2027, driven by a 30% CAGR from 2022 guidance of $415-$420 million. The company's 2022 guidance includes a gross margin of 68%-69% and projected adjusted EBITDA losses of $12.5 million to $17.5 million. iRhythm aims for a 15% adjusted EBITDA margin by 2027, with significant international market opportunities and operational excellence initiatives anticipated to yield over $250 million in annual savings.
iRhythm Technologies (NASDAQ: IRTC) will host an Analyst & Investor Day on September 21, 2022, in New York City. The event will begin at 9:00 a.m. ET and will be available via live webcast on the company’s investor website. A replay and additional materials will be accessible post-event.
iRhythm, a leader in digital healthcare, focuses on advancing cardiac care through wearable biosensors and cloud-based analytics, aiming to enhance arrhythmia detection and clinical management of patients.
iRhythm Technologies reported strong second quarter results for 2022, achieving $102.1 million in revenue, a 25.6% increase year-over-year. The gross margin improved to 68.8%, alongside a significant rise in gross profit to $70.2 million. Despite a net loss of $23.9 million or $0.80 per share, the company raised its full-year revenue guidance to between $415 million and $420 million. iRhythm continues to expand its executive team and aims to grow its market presence with innovations like the Zio Watch and increased Medicare pricing.
iRhythm Technologies (NASDAQ:IRTC) has announced its participation in the Canaccord Genuity 42nd Annual Growth Stock Conference on August 11, 2022, at 12:00 p.m. Eastern Time. The company, known for its innovative cardiac care solutions, will provide a live and archived webcast of the presentation on its website. iRhythm specializes in diagnosing cardiac arrhythmias through wearable biosensor devices and advanced data analytics, aiming to enhance patient management through improved arrhythmia detection.
iRhythm Technologies (NASDAQ:IRTC) announced leadership changes, appointing Brice Bobzien as Chief Financial Officer starting August 8, 2022, and Reyna Fernandez as Executive Vice President, Chief Human Resources Officer on July 25, 2022. Bobzien, previously at Dexcom, will focus on financial operations and growth, while Fernandez will drive HR strategies for global expansion. iRhythm aims to enhance operational effectiveness and efficiency with these appointments, aligning with its vision to lead in digital healthcare for cardiac care.
iRhythm Technologies has received FDA 510(k) clearance for its ZEUS System in conjunction with the Zio Watch, developed with Verily. This clinical-grade wearable aims to detect and monitor atrial fibrillation (AFib), integrating seamlessly into clinician workflows. The Zio Watch employs advanced algorithms for continuous monitoring and generating preliminary reports for physicians. Notably, the ACE algorithm achieved a 93.6% sensitivity and 99.1% specificity for AFib detection. The Zio Watch will be evaluated in a limited market in 2023.
iRhythm Technologies, Inc. (NASDAQ: IRTC) announced the resignation of Chief Commercial Officer Dave Vort, effective July 25, 2022. Vort will continue as a strategic advisor until March 31, 2023. Chad Patterson, formerly Chief Marketing Officer at Dexcom, joins as the new CCO. iRhythm estimates preliminary unit volumes for Q2 2022 are slightly ahead of expectations, with projected revenue for the year between $410 million and $420 million. The company will release its Q2 2022 financial results on August 4, 2022.
iRhythm Technologies (NASDAQ: IRTC) commented on the CMS Medicare Physician Fee Schedule Proposed Rule for 2023, released on July 7, 2022. The proposed rule includes updates to payment rates for long-term ECG monitoring services, specifically through CPT codes 93243 and 93247, used for reimbursement of the Zio XT service. Proposed national payment rates are $215 and $204, with potential rates ranging from $218 to $295 and $207 to $280 depending on geographic factors. iRhythm anticipates the impact on its full-year 2022 revenue guidance would be immaterial.
iRhythm Technologies, a leader in digital health care, announced its participation in the 42nd Annual William Blair Growth Stock Conference. The presentation is scheduled for June 8, 2022, at 2:40 p.m. Central Time. Interested parties can access the live and archived webcast via the company’s website.
iRhythm specializes in innovative cardiac care solutions, using wearable biosensor devices and advanced data analytics to improve the diagnosis of cardiac arrhythmias.